Tuberous xanthomas associated with olanzapine therapy and hypertriglyceridemia in the setting of a rare apolipoprotein E mutation

Endocrine Practice

Volumn 12, Issue 2, 2006, Pages 183-187

  Sinnott, Bridget P ^a   Mazzone, Theodore ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E2; BENZODIAZEPINE DERIVATIVE; CHOLESTEROL; OLANZAPINE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD; CASE REPORT; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; GENETICS; HUMAN; HYPERLIPOPROTEINEMIA TYPE 3; HYPERTRIGLYCERIDEMIA; MALE; POINT MUTATION; XANTHOMATOSIS;

ADULT; APOLIPOPROTEIN E2; APOLIPOPROTEINS E; BENZODIAZEPINES; CHOLESTEROL; HUMANS; HYPERLIPOPROTEINEMIA TYPE III; HYPERTRIGLYCERIDEMIA; MALE; POINT MUTATION; TRIGLYCERIDES; XANTHOMATOSIS;

EID: 33745384254     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.12.2.183     Document Type: Article

References (20)

1. Rall SC Jr, Weisgraber KH, Innerarity TL, Mahley RW. Structural basis for receptor binding heterogeneity of apolipoprotein E from type III hyperlipoproteinemic subjects. Proc Natl Acad Sci U S A. 1982;79:4696-4700.
2. de Villiers WJ, van der Westhuyzen DR, Coetzee GA, Henderson HE, Marais D. The apolipoprotein E2(Arg145Cys) mutation causes autosomal dominant type III hyperlipoproteinemia with incomplete penetrance. Arterioscler Thromb Vasc Biol. 1997;17:865-872.
3. Mahley RW, Rall SC Jr. Type III hyperlipoproteinemia (dyslipoproteinemia): the role of apolipoprotein E in normal and abnormal metabolism. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York, NY: McGraw-Hill, 2001: 2835-2862.
4. Utermann G, Hees M, Steinmetz A. Polymorphism of apolipoprotein E and occurrence of dysbetalipoproteinaemia in man. Nature. 1977;269:604-607.
5. Wilson PW, Myers RH, Larson MG, Ordovas JM, Wolf PA, Schaefer EJ. Apolipoprotein E alleles, dyslipidemia, and coronary heart disease: the Framingham Offspring Study. JAMA. 1994;272:1666-1671.
6. Poirier J, Davignon J, Bouthillier D, Kogan S, Bertrand P, Gauthier S. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet. 1993;342:697-699.
7. Hoffmann M, Scharnagl H, Panagiotou E, Banghard W, Wieland H, Marz W. Diminished LDL receptor and high heparin binding of apolipoprotein E2 Sendai associated with lipoprotein glomerulopathy. J Am Soc Nephrol. 2001;12:524-530.
8. Havel RJ, Chao Y, Windler EE, Kotite L, Guo LS. Isoprotein specificity in the hepatic uptake of apolipoprotein E and the pathogenesis of familial dysbetalipoproteinemia. Proc Natl Acad Sci U S A. 1980;77:4349-4353.
9. Weisgraber KH, Innerarity TL, Mahley RW. Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site. J Biol Chem. 1982;257:2518-2521.
10. Civeira F, Pocovi M, Cenarro A, et al. Apo E variants in patients with type III hyperlipoproteinemia. Atherosclerosis. 1996;127:273-282.
11. Smelt AH, de Beer F. Apolipoprotein E and familial dysbetalipoproteinemia: clinical, biochemical, and genetic aspects. Semin Vasc Med. 2004;4:249-257.
12. Rall SC Jr, Newhouse YM, Clarke HR, et al. Type III hyperlipoproteinemia associated with apolipoprotein E phenotype E3/3: structure and genetics of an apolipoprotein E variant. J Clin Invest. 1989;83:1095-1101.
13. Schneider WJ, Kovanen PT, Brown MS, et al. Familial dysbetalipoproteinemia: abnormal binding of mutant apolipoprotein E to low density lipoprotein receptors of human fibroblasts and membranes from liver and adrenal of rats, rabbits, and cows. J Clin Invest. 1981;68:1075-1085.
14. Mann WA, Gregg RE, Sprecher DL, Brewer HB Jr. Apolipoprotein E-1 Harrisburg: a new variant of apolipoprotein E dominantly associated with type III hyperlipoproteinemia. Biochem Biophys Acta. 1989;1005:239-244.
15. Moriyama K, Sasaki J, Matsunaga A, et al. Apolipoprotein E1 Lys-146 - Glu with type III hyperlipoproteinemia. Biochim Biophys Acta. 1992;1128:58-64.
16. de Knijff P, van den Maagdenberg AM, Stalenhoef AF, et al. Familial dysbetalipoproteinemia associated with apolipoprotein E3-Leiden in an extended multigeneration pedigree. J Clin Invest. 1991;88:643-655.
17. Horie Y, Fazio S, Westerlund JR, Weisgraber KH, Rall SC Jr. The functional characteristics of a human apolipoprotein E variant (cysteine at residue 142) may explain its association with dominant expression of type III hyperlipoproteinemia. J Biol Chem. 1992;267:1962-1968.
18. Kinon BJ, Basson BR, Gilmore JA, Tollefson GD. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry. 2001;62:92-100.
19. Moisan J, Gregoire JP, Gaudet M, Cooper D. Exploring the risk of diabetes mellitus and dyslipidemia among ambulatory users of atypical antipsychotics: a populationbased comparison of risperidone and olanzapine. Pharmacoepidemiol Drug Saf. 2005;14:427-436.
20. Chang HY, Ridky TW, Kimball AB, Hughes E, Oro AE. Eruptive xanthomas associated with olanzapine use. Arch Dermatol. 2003;139:1045-1048.